Theravance Biopharma, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $107.5M | $64.4M | $57.4M | $51.3M | $55.3M |
| Operating income | -$3.6M | -$46.9M | -$56.0M | -$92.0M | -$257.8M |
| Operating expenses | $111.1M | $111.3M | $113.5M | $143.3M | $313.1M |
| Cash from operations | $238.5M | -$11.5M | -$27.0M | -$187.0M | -$207.9M |
| Capital expenditure | $42,000 | $332,000 | $2.5M | $572,000 | $3.4M |
| Free cash flow | $238.5M | -$11.9M | -$29.5M | -$187.6M | -$211.3M |
| Share repurchases | — | $445,000 | $197.1M | $128.8M | — |
| Impairments | $0 | $4.5M | $0 | — | — |
| Total assets | $485.6M | $354.2M | $382.0M | $607.4M | $374.8M |
Shares outstanding 51.6M · Free float 37.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.